Sites
Tags
- A
- Abemaciclib
- Adenosine deaminase
- Aflibercept
- Alitretinoin
- Alvocidib
- American Society of Health-System Pharmacists
- Aminolevulinic acid
- Aminopterin
- Amsacrine
- An
- Anthracycline
- Anthraquinone
- Antimetabolite
- Arsenic trioxide
- Ascochyta
- Asparaginase
- Asparagine
- Atrasentan
- Axicabtagene ciloleucel
- Azacitidine
- B-cell chronic lymphocytic leukemia
- BEI
- Bei Fast
- Bei Nur
- Bendamustine
- Bexarotene
- Biological half-life
- Bleomycin
- Bortezomib
- Boxed warning
- Busulfan
- Cabazitaxel
- Camptotheca
- Camptothecin
- Capecitabine
- Capsule
- Carboplatin
- Carfilzomib
- Carmustine
- CAS Registry Number
- Celecoxib
- Cell Cycle
- ChEMBL
- Chemical formula
- Chemotherapy
- ChemSpider
- Chickpea
- Chlormethine
- Cisplatin
- Cladribine
- Clinical trial
- CLL
- Clofarabine
- Committee for Medicinal Products for Human Use
- Copanlisib
- Crosslinking of DNA
- Cyclin-dependent kinase
- Cyclophosphamide
- Cytarabine
- Dacarbazine
- Dactinomycin
- DailyMed
- Decitabine
- Denileukin diftitox
- Deoxyribonucleotide
- DGP
- Didymella rabiei
- DNA replication
- Docetaxel
- DOI
- Doxorubicin
- DrugBank
- Drug class
- Drug metabolism
- Drug nomenclature
- Endothelin receptor antagonist
- Enzyme inhibitor
- Epirubicin
- Etoposide
- European Chemicals Agency
- European Medicines Agency
- Exatecan
- Excretion
- Farnesyltransferase inhibitor
- FDA
- Fludarabine
- Fluorouracil
- Follicular lymphoma
- Food and Drug Administration
- Gemcitabine
- Halogenation
- Hemmen
- Histone deacetylase inhibitor
- Hydrazine
- Hydroxycarbamide
- Hypomethylating agent
- Idelalisib
- Ifosfamide
- Incyte
- Infection
- Intercalation
- Irinotecan
- Ixabepilone
- Ixazomib
- Jmol
- Kam Zu
- KEGG
- Kevan Shokat
- Leukopenia
- Lomustine
- Lucanthone
- Mechanical philosophy
- Medication
- MedlinePlus
- Melphalan
- Mercaptopurine
- Methotrexate
- Microtubule
- MIT
- Mitomycins
- Mitotic inhibitor
- Mitoxantrone
- Molar mass
- Nektar Therapeutics
- New
- Niraparib
- Nitrogen mustard
- Nitrosourea
- Oder
- Olaparib
- Omacetaxine mepesuccinate
- Onset of action
- Oral administration
- Orphan drug
- Oxaliplatin
- Paclitaxel
- Palbociclib
- Panobinostat
- PARP inhibitor
- Pemetrexed
- Pharmacokinetics
- Phases of clinical research
- Phosphodiesterase inhibitor
- Phosphoinositide 3-kinase inhibitor
- Photodynamic therapy
- Photosensitizer
- PI3K/AKT/mTOR pathway
- PIK3CG
- Platinum-based antineoplastic
- PMC
- Pneumonitis
- Podophyllum
- Polymerase chain reaction inhibitors
- Porphyrin
- Procarbazine
- Proteasome inhibitor
- Protein kinase inhibitor
- PubChem
- Public domain
- PubMed
- Purine analogue
- Pyrimidine analogue
- Raltitrexed
- Receptor antagonist
- Regulation of therapeutic goods
- Retinoid
- Retinoid X receptor
- Ribociclib
- Romidepsin
- Route of administration
- Seliciclib
- Semustine
- Sex steroid
- Signal
- Signal transduction
- S phase
- Streptomyces
- Streptozotocin
- Talimogene laherparepvec
- Taxane
- T-cell lymphoma
- TCR
- Temoporfin
- Temozolomide
- Testolactone
- ThioTEPA
- Tigilanol tiglate
- Tipifarnib
- Tisagenlecleucel
- Topotecan
- Trabectedin
- Tretinoin
- Type II topoisomerase
- Type I topoisomerase
- Unique Ingredient Identifier
- University of California, San Francisco
- Valrubicin
- Veliparib
- Venetoclax
- Verteporfin
- Vinblastine
- Vincristine
- Vinflunine
- Vinorelbine
- Vorinostat
- WHO Model List of Essential Medicines